scholarly journals Sphingomonas paucimobilis bacteremia and tricuspid valve endocarditis in a patient with intravenous drug use

IDCases ◽  
2022 ◽  
pp. e01399
Author(s):  
Wesley Tang ◽  
Sulagna Das ◽  
Satish Sarvepalli
2019 ◽  
Vol 12 (3) ◽  
pp. e227408
Author(s):  
Fatouma Sall ◽  
Anicet Adoubi ◽  
Nina Koffi ◽  
Herve Yangni-Angate

Tricuspid valve(TV) destruction with a remote history of endocarditis without known risk factors (ie, HIV, intravenous drug use, neoplasm, trauma) is rare. We describe the case of a TVs destruction in a 12-year-old non-HIV boy, with a 4-year history of endocarditis without known risk factors nor evidence regarding previous appropriately management.


2021 ◽  
pp. 201010582110666
Author(s):  
Huzairi Sani ◽  
Nada S Zulkufli ◽  
Yi L Gan ◽  
Ainur F Nadzir ◽  
Sazzli Kasim

Intravenous drug use, central catheters and intracardiac devices are known predispositions to right-sided infective endocarditis (IE). We report a case of tricuspid IE caused by Acinetobacter seifertii and Enterobacter bugandensis as a result of intravenous use of skin-whitening products bought online. Clinical implications and pharmaceutical regulations are briefly discussed.


2010 ◽  
Vol 3 (2) ◽  
pp. 78-80
Author(s):  
Joanne N Quiñones ◽  
Faunda Campbell ◽  
Kara M Coassolo ◽  
Gerald Pytlewski ◽  
Patricia Maran

Bacterial endocarditis in pregnancy is rare, usually resulting from preexisting cardiac lesions or intravenous drug use. We present an interesting case of tricuspid valve endocarditis in a pregnant woman and raise important points in the management of this condition during pregnancy.


1993 ◽  
Vol 38 (6) ◽  
pp. 655-656
Author(s):  
Terri Gullickson

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S224-S224
Author(s):  
Aryn M Andrzejewski ◽  
J Alex Viehman

Abstract Background Skin and soft tissue infections (SSTIs) are among the most prevalent infectious complications of intravenous drug use (IVDU). Given its polymicrobial nature, studies focusing on SSTIs in the general population may not be generalizable this group. We completed a retrospective chart review to better characterize the safety and efficacy of oral versus intravenous (IV) antibiotics for the treatment SSTIs in IVDU. Methods We reviewed patients admitted with bacterial SSTIs and IVDU from January 01, 2012 to December 31, 2019 based on ICD-10 codes. SSTIs complicated by bacteremia, endocarditis, bone or joint involvement on index admission were excluded. Patients who received < 48 hours of IV antibiotics were considered oral therapy, otherwise they were considered IV therapy. Patient comorbidities, incision and drainage (I&D) status, substance use, microbiology and antimicrobial data were reviewed. Results Of 231 eligible patients, 84 received oral therapy. There was no statistical difference in patient characteristics between the two therapy groups. Streptococcus anginosus group were the most common organisms found (33%) followed by Staphylococcus aureus (31%). There was no statistical difference between rates of readmission (p=0.87), recurrent primary site infection (p=1.00), repeat debridement (p=0.08) or occurrence of deep-seated infections within 90 days of treatment completion. No morality was observed. The oral group had shorter length of stay (3 vs. 5 days, p < 0.001) and shorter total duration of antibiotics (10 vs. 13 days, p < 0.001). Overall, 90% of those with abscess underwent I&D, which did not differ between therapy groups. Time to I&D was shorter (0 vs. 1 day, p=0.005) in the oral group. Patients who did not receive and I&D were more likely to be readmitted within 90 days (p=0.025). Conclusion In SSTIs related to IVDU, oral antibiotic therapy was noninferior to IV in terms of mortality, readmission, and deep-seated infection rates within 90 days of treatment completion and had a decreased length of stay and total treatment duration. A delay in I&D led to increased length of stay and lack of I&D increased readmission rate. Therefore, a prompt I&D may allow a safe and effective early transition to oral therapy in SSTIs related to IVDU. Disclosures All Authors: No reported disclosures


Sign in / Sign up

Export Citation Format

Share Document